This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Addressing Social Determinants of Health (SDOH) and Racial/Ethnic Disparities in Diabetes with Real-Time CGM

Learn More

Payer Perspectives on the Value of Real-Time Continuous Glucose Monitoring

Learn More

Lower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring

Learn More

CMS expands Medicare coverage for CGM, eliminating requirement of 4 fingersticks per day prior to accessing CGM

Learn More

Featured Article

"Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,” Andrew J. Karter, PhD

Learn More

Coverage News Update:

Effective January 1, 2022; Continuous Glucose Monitoring will be covered by Medi-Cal Rx as a pharmacy-billed medical supply benefit with an approved pharmacy prior authorization for Type 1 patients that meet criteria. Click here for the full update.


In The News:

FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System


Featured Resource:

ADA Standards of Medical Care: Recommendations for Continuous Glucose Monitoring


The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen. The findings from the MOBILE study likewise demonstrate the value of rtCGM across typically underserved demographics of patients impacted by social determinants of health (SDOH). Taking the ADA recommendations into consideration, payers are formulating coverage policies that facilitate appropriate access to rtCGM, improved outcomes in T2D, and proven per-member-per-month (PMPM) cost savings.

Featured Publications



Rethinking Diabetes Care In The Digital Age – Findings from the 2021 Digital Quality Summit 


Expanding Medicaid Access to Continuous Glucose Monitors


Emerging Landscape of Continuous Glucose Monitoring

Diabetes Technology & Therapeutics


Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes

The Journal of the American Medical Association


Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicenter, randomized controlled trial

The Lancet


Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial

The Journal of the American Medical Association


Recent News


CMS revised Medicare coverage criteria for therapeutic CGMs. Most notably, eliminating a requirement that beneficiaries use four fingerstick tests per day prior to accessing CGM. Effective July 18, 2021.

Centers for Medicare & Medicaid Services


Real-time CGM lowers HbA1c, reduces ED visits in insulin-treated diabetes

Endocrine Today



Advisory Board

Joseph Albright, PharmD

Manager, Clinical Pharmacy Services
BlueCross BlueShield North Carolina
Read More

Jeffrey D. Dunn, PharmD, MBA

(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
MagellanRx Management
Read More

Daniel DeSalvo, MD

Assistant Professor of Pediatrics
Director of Strategic Collaboration
Diabetes Clinic CPT Co-Director
Section of Pediatric Diabetes & Endocrinology
Baylor College of Medicine/Texas Children's Hospital
Read More

Latest Expert Interview

Archived Interviews

Stay Connected

PHP Code Snippets Powered By :